SpinalMotion is one of a small number of second-generation companies that hope to follow in the path of the first artificial disc companies, with novel technologies and a more measured assessment of the market, especially the lumbar disc segment. The ultimate challenge for SpinalMotion may not be gaining market share, but finding an appropriate exit for its investors.
by David Cassak
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
